Search

Displaying results 4581 - 4590 of 10000 in total
  1. Drug

    Methyl aminolevulinate

    go.drugbank.com/drugs/DB00992
    ApprovedInvestigational

    Methyl aminolevulinate is a prodrug that is metabolised to Protoporphyrin IX (a photosensitizer) used in photodynamic therapy.

  2. Drug

    Fenretinide

    go.drugbank.com/drugs/DB05076
    Investigational

    A synthetic retinoid that is used orally as a chemopreventive against prostate cancer and in women at risk of developing contralateral breast cancer. It is also effective as an antineoplastic agent.

  3. Drug

    Elacytarabine

    go.drugbank.com/drugs/DB05494
    Investigational

    Elacytarabine is a fatty acid derivative of [cytarabine], an approved cytotoxic cancer drug. Cytarabine has limitations such as minimal uptake in solid tumours and is only used to treat leukaemia. … Elacytarabine is a patented new chemical entity of the nucleoside analog class, with improved biological properties and the potential to treat solid tumours such as non-small cell lung cancer, malignant

  4. Drug

    Padeliporfin

    go.drugbank.com/drugs/DB15575
    ApprovedInvestigational

    Padeliporfin is a water-soluble chlorophyll derivative and cytotoxic photosensitizer used for vascular-targeted photodynamic therapy for malignancies. … [A244559] Vascular-targeted photodynamic therapy (VTP), or vascular targeted photochemotherapy, is a focal treatment for localized prostate cancer.

  5. Drug

    EGEN-001

    go.drugbank.com/drugs/DB05953
    Investigational

    EGEN-001 is a novel non-viral vector consisting of a plasmid DNA encoding the human gene for interleukin 12 (IL-12) and a biocompatible, biodegradable delivery polymer with potential antineoplastic activity

  6. Drug

    Itopride

    go.drugbank.com/drugs/DB04924
    Investigational

    Itopride is a dopamine D2 antagonist with acetylcholinesterase inhibitory actions.

  7. Drug

    AS1409

    go.drugbank.com/drugs/DB05182
    Investigational

    AS1409 is a genetically engineered fusion protein made up of two distinct components. One is the cytokine IL12, which has anti-cancer activity. The other is an antibody that targets tumours. … It is developed by Antisoma is in a phase I of clinical trial for the treatment of renal cancer and melanoma.

  8. Drug

    POT-4

    go.drugbank.com/drugs/DB06056
    Investigational

    POT-4 is a peptide that specifically inhibits complement activation and is initially being developed for the treatment of age-related macular degeneration (AMD).

  9. Drug

    C326

    go.drugbank.com/drugs/DB06017
    Experimental

    The drug is composed of an IL-6–binding trimer and a IgG-binding domain. … C326 is an investigational compound under investigation in clinical trial NCT00353756 (Phase 1 Study of Safety and Biological Effects of C326, an Inhibitor of IL-6, in Crohn's Disease) for the treatment

  10. Drug

    TAK-475

    go.drugbank.com/drugs/DB05317
    Investigational

    TAK-475 is a "squalene synthase inhibitor", a type of cholesterol-lowering drug that has not yet been brought to market.